Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 67

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 67
---
 in the future, and we may not realize the benefits of such transactions. We may enter into licensing arrangements and strategic transactions to acquire and advance new assets or product candidates in the future, including strategic partnerships, in-licensingof product candidates, strategic collaborations, joint ventures, restructurings, divestitures, acquisitions of companies, asset purchases, business combinations, and investments. Any future transactions that we enter into may not be successful. In particular, the success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that:

| • |     | collaborators have significant discretion in determining the efforts and resources that they will apply to 
 collaborations;                                                                                            |

| • |     | collaborators may not pursue development and commercialization of our product candidate or may elect not to                                                                                                                                         
 continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business 
 combination that diverts resources or creates competing priorities;                                                                                                                                                                                 |

| • |     | collaborators could independently develop, or develop with third parties, products that compete directly or 
 indirectly with our product candidate;                                                                      |

| • |     | a collaborator with marketing, manufacturing, and distribution rights to one or more products may not commit 
 sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;            |

| • |     | we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; |

| • |     | collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual                                                                                                                
 property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; |

| • |     | disputes may arise between us and a collaborator that causes the delay or termination of the research,                                                                 
 development or commercialization of our future product candidates or that results in costly litigation or arbitration that diverts management attention and resources; |

| • |     | collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue 
 further development or commercialization of the applicable future product candidates;                       |

| • |     | collaborators may own or co-own intellectual property covering our                                                                                                                    
 product candidate that results from our collaborating with them, and in such cases, we would not have the